Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in cholangiocarcinoma

Nuvectis Pharma, Inc.

FDA granted Orphan Drug Designation to NXP800 for cholangiocarcinoma.
NXP800 is an oral small molecule targeting ARID1a-mutated cancers.
Phase 1b trial ongoing in ARID1a-mutated ovarian carcinoma; cholangiocarcinoma expansion planned.
CEO Ron Bentsur cites unmet medical need in cholangiocarcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.